Hydrogenology
Source-linked study record

Oral intake of hydrogen-rich water inhibits intimal hyperplasia in arterialized vein grafts in rats

Sun Q, Kawamura T, Masutani K, Peng X, Sun Q, Stolz DB, Pribis JP, Billiar TR, Sun X, Bermudez CA, Toyoda Y, Nakao A. · Cardiovascular Research. 2012;94(1):144-153.

PreclinicalH₂-rich waterPublished 2012Source checked
Study record, not medical adviceThis record reports what the source states. It is not medical advice and does not establish that molecular hydrogen is effective, safe or appropriate for any person.
Quick summary

Study at a glance

Evidence type

Preclinical

Population or model

Lewis-rat abdominal aortic vein graft recipients, plus rat aortic smooth-muscle cells and human umbilical-vein endothelial cells in culture.

Intervention and dose

Hydrogen-rich drinking water ad libitum immediately after vein grafting until tissue collection. · A magnesium stick generated 0.55-0.65 mmol/L H₂ water at pH 9.2-9.9, replaced every 24 hours. Separate culture medium contained 0.6 mmol/L H₂.

Duration

One or six weeks of drinking-water exposure after grafting; in-vitro assays through 24-72 hours.

Reported result

H₂ water increased blood H₂ transiently, reduced six-week intimal hyperplasia and multiple injury/inflammatory/migration measures, and preserved the endothelial surface. H₂ medium suppressed smooth-muscle migration but did not affect proliferation through 72 hours; H₂ intake did not affect ERK1/2 phosphorylation.

Main limitation

Preclinical surgical model, outcome-specific small groups, ad-libitum intake not quantified per animal, pH differed from ordinary water, multiple mechanistic endpoints and no graft-patency clinical endpoint. Public/foundation/NIH support was reported; authors declared no conflicts.

Evidence and classification

What kind of evidence is this?

Evidence type

Preclinical

Reported design

Randomized three-water rat vein-graft experiment with blood-H₂ kinetics and vascular-cell culture components

Research topic

Cardiovascular and circulatory health

Administration form

H₂-rich water

Information not yet classified

Some editorial classification fields are still pending. The source-reported outcomes and result are shown below; Hydrogenology does not infer a positive or negative signal from prose automatically.

Reported in the source

Methods

Population or model

Lewis-rat abdominal aortic vein graft recipients, plus rat aortic smooth-muscle cells and human umbilical-vein endothelial cells in culture.

Sample

Tissue outcomes used n=5 per drinking-water group at one week and approximately n=5-6 at six weeks; culture experiments were repeated at least three times. A single total animal count is not reported.

Duration

One or six weeks of drinking-water exposure after grafting; in-vitro assays through 24-72 hours.

Intervention

Hydrogen-rich drinking water ad libitum immediately after vein grafting until tissue collection.

Hydrogen form

H₂ dissolved in drinking water — H₂ only, not Brown's gas.

Dose or H₂ specification

A magnesium stick generated 0.55-0.65 mmol/L H₂ water at pH 9.2-9.9, replaced every 24 hours. Separate culture medium contained 0.6 mmol/L H₂.

Comparator

Regular tap water and hydrogen water degassed for 48 hours, plus naive vein controls and ordinary culture medium.

Reported, not endorsed

Outcomes and reported result

Outcomes measured

Blood H₂ kinetics, intimal hyperplasia, macrophage/endothelial morphology, oxidative and inflammatory markers, MMP-2/9, smooth-muscle migration/proliferation and endothelial-cell injury.

Reported result

H₂ water increased blood H₂ transiently, reduced six-week intimal hyperplasia and multiple injury/inflammatory/migration measures, and preserved the endothelial surface. H₂ medium suppressed smooth-muscle migration but did not affect proliferation through 72 hours; H₂ intake did not affect ERK1/2 phosphorylation.

Extraction completeness

The complete free PMC article was checked for water preparation/concentration, comparators, timing, outcome-specific sample sizes, animal and cell outcomes, positive and null findings, funding and conflict declaration.

A reported association, difference or mechanism is not automatically a clinical benefit.

Interpretation limits

Limitations and applicability

Main methodological cautions

Preclinical surgical model, outcome-specific small groups, ad-libitum intake not quantified per animal, pH differed from ordinary water, multiple mechanistic endpoints and no graft-patency clinical endpoint. Public/foundation/NIH support was reported; authors declared no conflicts.

Applies directly to

Arterialized vein grafts in rats and vascular cells; it does not establish prevention of human bypass-graft failure.

No single-study GRADE certainty rating is assigned. Read how records and evidence assessments are prepared.

Sources and status

Sources and record status

Identifiers

PMID: 22287575 · DOI: 10.1093/cvr/cvs024

Publisher access

Free full article in PubMed Central.

Extraction basis

Complete PMC article and PubMed metadata; full-text extraction checked 9 August 2026.

Last reviewed

10 August 2026

Help the next reader

Help people check the facts before they buy.

Hydrogenology keeps 665 source-checked records accessible without advertising or product promotion.

Support independent access
Help us correct the recordReport a discrepancy

Send the exact difference between this page and the linked source. The study reference is attached automatically.